The TNF increase was significantly lower in the treated groups compared to the BD group: Coversin group FC 9.4 (4.7–14) (p = 0.009), anti-CD14 group FC 8.7 (4.5–12) (p = 0.004) and dual treatment group FC 9.9 (6.2–13) (p = 0.036) (Fig. 4A). Here, CD14 is linked to Behcet disease.